ELSEVIER

Diabetes Research and Clinical Practice 25 (1994) 211–213

DIABETES RESEARCH AND CLINICAL PRACTICE

# Author index

## Volume 25 (1994)

Abugova, I.A., see Shishko, P.I. **25**, 1
Agardh, C.-D., see Karlson, B. **25**, 111
Akabane, S., see Inoue, I. **25**, 199
Al-Mofti, S., see El-Reshaid, K. **25**, 207
Anichini, R., see Innocenti, F. **25**, 161
Aoki, K., see Wasada, T. **25**, 191
Arii, H., see Wasada, T. **25**, 191
Armentano, V., see Palma, V. **25**, 91
Asou, N., see Noda, K. **25**, 27
Azevedo, M.J., A.F. Pinotti, J.L. Gross, A.G. Stumpf, J.P. Ribeiro, Preserved left ventricular systolic and diastolic function in normoalbuminuric insulin-dependent diabetic patients with glomerular hyperfiltration **25**, 103

Basso, M., see Kamijo, M. **25**, 117
Brismar, T., see Lindström, P. **25**, 177
Bruce, R., M. Rutland, T. Cundy, Glomerular hyperfiltration in young Polynesians with type 2 diabetes **25**, 155

Cherian, P.V., see Kamijo, M. **25**, 117
Cundy, T., see Bruce, R. **25**, 155

Damodaran, C., see Subramanian, V.S. **25**, 51
De Giorgio, L.A., see Innocenti, F. **25**, 161
Dreval, A.V., see Shishko, P.I. **25**, 1

Ebata, K., see Itagaki, I. **25**, 141
El-Reshaid, K., S. Al-Mofti, N.R. Stepic, Induction of insulin resistance by autoantibodies to insulin receptors following on an acute Coxsackie B4 infection **25**, 207
Esmatjes, E., see Vidal, J. **25**, 19

Fabbri, A., see Innocenti, F. **25**, 161
Ferrer, J.P., see Vidal, J. **25**, 19
Finegood, D.T., see Rowe, R.E. **25**, 131
Fujimoto, H., see Funasako, M. **25**, 35
Fujimoto, K., see Funasako, M. **25**, 35
Funakoshi, A., see Tateishi, K. **25**, 43
Funasako, M., M. Taniji, K. Fujimoto, M. Ohata, Y. Higashimoto, K. Uetani, T. Suruda, S. Nakai, H. Fujimoto, Y. Sakagami, Effect of aging on plasma 1,5-anhydroglucitol levels in humans and rats **25**, 35

Gomis, R., see Vidal, J. **25**, 19
Goncharov, V.C., see Shishko, P.I. **25**, 1
González-Clemente, J.M., see Vidal, J. **25**, 19
Gross, J.L., see Azevedo, M.J. **25**, 103

Hanada, H., see Wasada, T. **25**, 191
Haneda, M., see Itagaki, I. **25**, 141
Hawthorne, G., A. Snodgrass, M. Tunbridge, Outcome of diabetic pregnancy and glucose intolerance in pregnancy: an audit of fetal loss in Newcastle General Hospital 1977 — 1990 **25**, 183
Higashimoto, Y., see Funasako, M. **25**, 35
Hirose, H., H. Maruyama, K. Ito, K. Kido, K. Koyama, T. Saruta, Effects of diazoxide on $\alpha$- and $\beta$-cell function in isolated perfused rat pancreas **25**, 77
Hohman, T.C., see Kamijo, M. **25**, 117
Hoshino, T., K. Yamada, K. Masuoka, I. Tsuboi, K. Itoh, K. Nonaka, K. Oizumi, Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus **25**, 97

Innocenti, F., A. Fabbri, R. Anichini, S. Tuci, G. Pettinà, F. Vannucci, L.A. De Giorgio, G. Seghieri, Indications of reduced pulmonary function in type 1 (insulin-dependent) diabetes mellitus **25**, 161
Inoue, I., K. Takahashi, S. Katayama, S. Akabane, K. Negishi, M. Suzuki, J. Ishii, S. Kawazu, Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance **25**, 199
Ishibashi, F., Glomerular clearance and tubular reabsorption of transferrin in microtransferrinuric patients with non-insulin-dependent diabetes **25**, 169
Ishii, J., see Inoue, I. **25**, 199
Isogai, S., see Oshima, Y. **25**, 83
Itagaki, I., K. Shimizu, Y. Kamanaka, K. Ebata, R. Kikkawa, M. Haneda, Y. Shigeta, The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats **25**, 141
Ito, K., see Hirose, H. **25**, 77
Itoh, K., see Hoshino, T. **25**, 97
Itou, T., see Takahashi, Y. **25**, 13
Iwamoto, N., see Tateishi, K. **25**, 43

Kamanaka, Y., see Itagaki, I. **25**, 141

0168-8227/94/$07.00 © 1994 Elsevier Science Ireland Ltd. All rights reserved

Kamijo, M., M. Basso, P.V. Cherian, T.C. Hohman, A.A.F. Sima, Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy **25**, 117
Karlson, B., C.-D. Agardh, Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus **25**, 111
Katayama, S., see Inoue, I. **25**, 199
Katsumori, K., see Wasada, T. **25**, 191
Kawazu, S., see Inoue, I. **25**, 199
Kido, K., see Hirose, H. **25**, 77
Kikkawa, R., see Itagaki, I. **25**, 141
Koyama, K., see Hirose, H. **25**, 77
Krishnaswami, C.V., see Subramanian, V.S. **25**, 51
Kuroki, H., see Wasada, T. **25**, 191

Leech, N.J., see Rowe, R.E. **25**, 131
Lindström, P., T. Brismar, A.A.F. Sima, Impaired recovery in diabetic rat nerve following anoxic conduction block **25**, 177

Maruyama, A., see Wasada, T. **25**, 191
Maruyama, H., see Hirose, H. **25**, 77
Masuoka, K., see Hoshino, T. **25**, 97
Matsuoka, Y., see Tateishi, K. **25**, 43
McCulloch, D.K., see Rowe, R.E. **25**, 131
Mogami, K., see Oshima, Y. **25**, 83
Mohan, V., see Premalatha, G. **25**, 137
Motomatu, T., see Noda, K. **25**, 27

Nakai, S., see Funasako, M. **25**, 35
Nawata, H., see Noda, K. **25**, 27
Negishi, K., see Inoue, I. **25**, 199
Noda, K., F. Umeda, N. Asou, T. Motomatu, H. Nawata, Correlation of peripheral nerve fatigue following vibratory stimulation with hyperglycemia in diabetic patients **25**, 27
Nolfe, G., see Palma, V. **25**, 91
Nonaka, K., see Hoshino, T. **25**, 97

Ohata, M., see Funasako, M. **25**, 35
Ohe, K., see Oshima, Y. **25**, 83
Ohuchi, H., see Oshima, Y. **25**, 83
Oizumi, K., see Hoshino, T. **25**, 97
Omori, Y., see Takahashi, Y. **25**, 13
Omori, Y., see Wasada, T. **25**, 191
Oshima, Y., S. Isogai, K. Mogami, H. Ohuchi, K. Ohe, Protective effect of heparin on renal glomerular anionic sites of streptozotocin-injected rats **25**, 83
Owada, K., see Takahashi, Y. **25**, 13

Palma, V., L.L. Serra, V. Armentano, F.P. Serra, G. Nolfe, Somatosensory evoked potentials in non-insulin-dependent diabetics with different degrees of neuropathy **25**, 91
Pettinà, G., see Innocenti, F. **25**, 161
Pinotti, A.F., see Azevedo, M.J. **25**, 103
Premalatha, G., V. Mohan, Fibrocalculous pancreatic diabetes in infancy — two case reports **25**, 137

Ramachandran, A., C. Snehalatha, P. Shyamala, V. Vijay, M. Viswanathan, Prevalence of diabetes in pregnant women — a study from Southern India **25**, 71
Ribeiro, J.P., see Azevedo, M.J. **25**, 103
Rodés, J., see Vidal, J. **25**, 19
Rowe, R.E., N.J. Leech, D.T. Finegood, D.K. McCulloch, Retrograde versus antegrade cannulation in the intravenous glucose tolerance test **25**, 131
Rutland, M., see Bruce, R. **25**, 155

Saito, S., see Wasada, T. **25**, 191
Sakagami, Y., see Funasako, M. **25**, 35
Salmeron, J.M., see Vidal, J. **25**, 19
Saruta, T., see Hirose, H. **25**, 77
Seghieri, G., see Innocenti, F. **25**, 161
Serra, F.P., see Palma, V. **25**, 91
Serra, L.L., see Palma, V. **25**, 91
Shigeta, Y., see Itagaki, I. **25**, 141
Shima, K., see Tateishi, K. **25**, 43
Shimizu, K., see Itagaki, I. **25**, 141
Shishko, P.I., A.V. Dreval, I.A. Abugova, I.U. Zajarny, V.C. Goncharov, Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion **25**, 1
Shyamala, P., see Ramachandran, A. **25**, 71
Sima, A.A.F., see Kamijo, M. **25**, 117
Sima, A.A.F., see Lindström, P. **25**, 177
Snehalatha, C., see Ramachandran, A. **25**, 71
Snodgrass, A., see Hawthorne, G. **25**, 183
Stepic, N.R., see El-Reshaid, K. **25**, 207
Stumpf, A.G., see Azevedo, M.J. **25**, 103
Subramanian, V.S., C.V. Krishnaswami, C. Damodaran, HLA, ESD, GLOI, C3 and HP polymorphisms and juvenile insulin dependent diabetes mellitus in Tamil Nadu (South India) **25**, 51
Suruda, T., see Funasako, M. **25**, 35
Suzuki, M., see Inoue, I. **25**, 199

Takahashi, K., see Inoue, I. **25**, 199
Takahashi, Y., S. Takayama, T. Itou, K. Owada, Y. Omori, Effect of glycemic control on vitamin $B_{12}$ metabolism in diabetes mellitus **25**, 13
Takayama, S., see Takahashi, Y. **25**, 13
Taniji, M., see Funasako, M. **25**, 35
Tateishi, K., K. Shima, A. Funakoshi, Y. Yasunami, N. Iwamoto, Y. Matsuoka, Glucagon-like peptide-1 (GLP-1) molecular forms in human pancreatic endocrine tumors resemble those in intestine rather than pancreas **25**, 43
Thai Multicenter Research, Vascular complications in non-insulin dependent diabetics in Thailand **25**, 61
Tsuboi, I., see Hoshino, T. **25**, 97
Tuci, S., see Innocenti, F. **25**, 161
Tunbridge, M., see Hawthorne, G. **25**, 183

Uetani, K., see Funasako, M. **25**, 35
Umeda, F., see Noda, K. **25**, 27

Vannucci, F., see Innocenti, F. **25**, 161
Vidal, J., J.P. Ferrer, E. Esmatjes, J.M. Salmeron, J.M. González-Clemente, R. Gomis, J. Rodés, Diabetes mellitus in patients with liver cirrhosis **25**, 19
Vijay, V., see Ramachandran, A. **25**, 71
Viswanathan, M., see Ramachandran, A. **25**, 71

Wasada, T., H. Kuroki, H. Arii, A. Maruyama, K. Aoki, K. Katsumori, S. Saito, H. Hanada, Y. Omori, Relationship between insulin resistance and risk factors for cardiovascular disease in Japanese non-insulin-dependent diabetic patients **25**, 191

Yamada, K., see Hoshino, T. **25**, 97
Yasunami, Y., see Tateishi, K. **25**, 43

Zajarny, I.U., see Shishko, P.I. **25**, 1

ELSEVIER

Diabetes Research and Clinical Practice 25 (1994) 215–218

DIABETES RESEARCH AND CLINICAL PRACTICE

# Subject index

## Volume 25 (1994)

**Adenosine deaminase**; Diabetes mellitus; Adenosine deaminase isoenzymes **25**, 97

**Adenosine deaminase isoenzymes**; Diabetes mellitus; Adenosine deaminase **25**, 97

**Aging**; 1,5-Anhydroglucitol; Diabetes mellitus; Humans; Rats **25**, 35

**Albuminuria**; Type 1 (insulin-dependent) diabetes mellitus; Lung functional tests; Diabetic microangiopathy **25**, 161

**Aldose reductase inhibitor**; Diabetic nephropathy; Glomerular morphometry; Mesangial expansion; Polyol pathway **25**, 141

**1,5-Anhydroglucitol**; Aging; Diabetes mellitus; Humans; Rats **25**, 35

**Anionic site**; Urinary albumin excretion; Streptozotocin-injected rat; Heparin **25**, 83

**Anoxia**; Diabetes mellitus; Diabetic neuropathy; Ischemia; Nerve conduction; BB-Wistar rat **25**, 177

**Anti-insulin receptor antibody**; Insulin resistance; Diabetes mellitus; Coxsackie B **25**, 207

**ARI-treatment**; Galactosemia; Axo-glial dysjunction; Regeneration **25**, 117

**ATP-sensitive potassium channels**; Diabetes mellitus; Insulin; Glucagon **25**, 77

**Axo-glial dysjunction**; Galactosemia; ARI-treatment; Regeneration **25**, 117

**BB-Wistar rat**; Diabetes mellitus; Diabetic neuropathy; Anoxia; Ischemia; Nerve conduction **25**, 177

**Bezafibrate**; Oral glucose (75 g) tolerance test; Non-esterified fatty acid; C-peptide/insulin ratio; Non-obese impaired glucose tolerance **25**, 199

**C-peptide/insulin ratio**; Oral glucose (75 g) tolerance test; Non-esterified fatty acid; Non-obese impaired glucose tolerance; Bezafibrate **25**, 199

**Cardiovascular risk factors**; Insulin resistance; Non-insulin-dependent diabetes mellitus (NIDDM); Euglycemic hyperinsulinemic clamp **25**, 191

**Childhood onset**; Fibrocalculous pancreatic diabetes; Tropical calcific pancreatitis; Pancreatic calculi; Chronic pancreatitis **25**, 137

**Chronic pancreatitis**; Fibrocalculous pancreatic diabetes; Childhood onset; Tropical calcific pancreatitis; Pancreatic calculi **25**, 137

**Cirrhosis**; Diabetes mellitus; Insulin secretion **25**, 19

**Coxsackie B**; Insulin resistance; Anti-insulin receptor antibody; Diabetes mellitus **25**, 207

**Diabetes**; Impaired glucose tolerance; Pregnancy; Fetal outcome **25**, 183

**Diabetes in pregnancy**; Gestational diabetes; Glucose intolerance in pregnancy **25**, 71

**Diabetes mellitus**; 1,5-Anhydroglucitol; Aging; Humans; Rats **25**, 35

**Diabetes mellitus**; Adenosine deaminase; Adenosine deaminase isoenzymes **25**, 97

**Diabetes mellitus**; ATP-sensitive potassium channels; Insulin; Glucagon **25**, 77

**Diabetes mellitus**; Cirrhosis; Insulin secretion **25**, 19

0168-8227/94/$07.00 © 1994 Elsevier Science Ireland Ltd. All rights reserved

**Diabetes mellitus**; Diabetic neuropathy; Anoxia; Ischemia; Nerve conduction; BB-Wistar rat **25**, 177

**Diabetes mellitus**; Insulin resistance; Anti-insulin receptor antibody; Coxsackie B **25**, 207

**Diabetes mellitus**; Vibratory perception threshold; Profound nerve fatigue; Repetitive nerve stimulation; Fasting hyperglycemia **25**, 27

**Diabetes mellitus**; Vitamin $B_{12}$; Glycemic control; Total $B_{12}$ binding capacity **25**, 13

**Diabetic complications**; Non-insulin dependent diabetes mellitus; Microvascular complications; Macrovascular complications **25**, 61

**Diabetic microangiopathy**; Type 1 (insulin-dependent) diabetes mellitus; Lung functional tests; Albuminuria **25**, 161

**Diabetic nephropathy**; Aldose reductase inhibitor; Glomerular morphometry; Mesangial expansion; Polyol pathway **25**, 141

**Diabetic nephropathy**; Glomerular filtration rate; Hyperfiltration; Polynesian **25**, 155

**Diabetic neuropathy**; Diabetes mellitus; Anoxia; Ischemia; Nerve conduction; BB-Wistar rat **25**, 177

**Diabetic neuropathy**; Somatosensory evoked potentials; Non-insulin-dependent diabetes; Nerve conduction velocity **25**, 91

**Disease association**; JIDDM; HLA; Genetic markers **25**, 51

**Doppler echocardiography**; Type 1 diabetes mellitus; Glomerular hyperfiltration **25**, 103

**Euglycemic hyperinsulinemic clamp**; Insulin resistance; Non-insulin-dependent diabetes mellitus (NIDDM); Cardiovascular risk factors **25**, 191

**Fasting hyperglycemia**; Vibratory perception threshold; Profound nerve fatigue; Repetitive nerve stimulation; Diabetes mellitus **25**, 27

**Fetal outcome**; Diabetes; Impaired glucose tolerance; Pregnancy **25**, 183

**Fibrocalculous pancreatic diabetes**; Childhood onset; Tropical calcific pancreatitis; Pancreatic calculi; Chronic pancreatitis **25**, 137

**Galactosemia**; Axo-glial dysjunction; ARI-treatment; Regeneration **25**, 117

**Genetic markers**; JIDDM; HLA; Disease association **25**, 51

**Gestational diabetes**; Diabetes in pregnancy; Glucose intolerance in pregnancy **25**, 71

**Glomerular clearance**; Microtransferrinuria; Tubular reabsorption; Non-insulin-dependent diabetes **25**, 169

**Glomerular filtration rate**; Diabetic nephropathy; Hyperfiltration; Polynesian **25**, 155

**Glomerular hyperfiltration**; Doppler echocardiography; Type 1 diabetes mellitus **25**, 103

**Glomerular morphometry**; Aldose reductase inhibitor; Diabetic nephropathy; Mesangial expansion; Polyol pathway **25**, 141

**GLP-1(1–36) amide**; Glucagon-like peptide-1 (GLP-1)(7–36) amide; Glucagonoma; Insulinoma **25**, 43

**Glucagon**; ATP-sensitive potassium channels; Diabetes mellitus; Insulin **25**, 77

**Glucagon-like peptide-1 (GLP-1)(7–36) amide**; GLP-1(1–36) amide; Glucagonoma; Insulinoma **25**, 43

**Glucagonoma**; Glucagon-like peptide-1 (GLP-1)(7–36) amide; GLP-1(1–36) amide; Insulinoma **25**, 43

**Glucose intolerance in pregnancy**; Diabetes in pregnancy; Gestational diabetes **25**, 71

**Glycemic control**; Vitamin $B_{12}$; Total $B_{12}$ binding capacity; Diabetes mellitus **25**, 13

**Heparin**; Urinary albumin excretion; Streptozotocin-injected rat; Anionic site **25**, 83

**HLA**; JIDDM; Genetic markers; Disease association **25**, 51

**Human**; IDDM; Prediction; IVGTT; Reproducibility **25**, 131

**Humans**; 1,5-Anhydroglucitol; Aging; Diabetes mellitus; Rats **25**, 35

**Hyperfiltration**; Diabetic nephropathy; Glomerular filtration rate; Polynesian **25**, 155

**IDDM**; Human; Prediction; IVGTT; Reproducibility **25**, 131

**Impaired glucose tolerance**; Diabetes; Pregnancy; Fetal outcome **25**, 183

**Insulin**; ATP-sensitive potassium channels; Diabetes mellitus; Glucagon **25**, 77

**Insulin regimens**; Metabolic control; Quality of life; Insulin-dependent diabetes mellitus **25**, 111

**Insulin resistance**; Anti-insulin receptor antibody; Diabetes mellitus; Coxsackie B **25**, 207

**Insulin resistance**; Non-insulin-dependent diabetes mellitus (NIDDM); Cardiovascular risk factors; Euglycemic hyperinsulinemic clamp **25**, 191

**Insulin secretion**; Cirrhosis; Diabetes mellitus **25**, 19

**Insulin-dependent diabetes mellitus**; Insulin regimens; Metabolic control; Quality of life **25**, 111

**Insulin-like growth factor**; Intraportal insulin infusion; Umbilical vein **25**, 1

**Insulinoma**; Glucagon-like peptide-1 (GLP-1)(7–36) amide; GLP-1(1–36) amide; Glucagonoma **25**, 43

**Intraportal insulin infusion**; Umbilical vein; Insulin-like growth factor **25**, 1

**Ischemia**; Diabetes mellitus; Diabetic neuropathy; Anoxia; Nerve conduction; BB-Wistar rat **25**, 177

**IVGTT**; IDDM; Human; Prediction; Reproducibility **25**, 131

**JIDDM**; HLA; Genetic markers; Disease association **25**, 51

**Lung functional tests**; Type 1 (insulin-dependent) diabetes mellitus; Diabetic microangiopathy; Albuminuria **25**, 161

**Macrovascular complications**; Non-insulin dependent diabetes mellitus; Diabetic complications; Microvascular complications **25**, 61

**Mesangial expansion**; Aldose reductase inhibitor; Diabetic nephropathy; Glomerular morphometry; Polyol pathway **25**, 141

**Metabolic control**; Insulin regimens; Quality of life; Insulin-dependent diabetes mellitus **25**, 111

**Microtransferrinuria**; Glomerular clearance; Tubular reabsorption; Non-insulin-dependent diabetes **25**, 169

**Microvascular complications**; Non-insulin dependent diabetes mellitus; Diabetic complications; Macrovascular complications **25**, 61

**Nerve conduction**; Diabetes mellitus; Diabetic neuropathy; Anoxia; Ischemia; BB-Wistar rat **25**, 177

**Nerve conduction velocity**; Diabetic neuropathy; Somatosensory evoked potentials; Non-insulin-dependent diabetes **25**, 91

**Non-esterified fatty acid**; Oral glucose (75 g) tolerance test; C-peptide/insulin ratio; Non-obese impaired glucose tolerance; Bezafibrate **25**, 199

**Non-insulin dependent diabetes mellitus**; Diabetic complications; Microvascular complications; Macrovascular complications **25**, 61

**Non-insulin-dependent diabetes**; Diabetic neuropathy; Somatosensory evoked potentials; Nerve conduction velocity **25**, 91

**Non-insulin-dependent diabetes**; Microtransferrinuria; Glomerular clearance; Tubular reabsorption **25**, 169

**Non-insulin-dependent diabetes mellitus (NIDDM)**; Insulin resistance; Cardiovascular risk factors; Euglycemic hyperinsulinemic clamp **25**, 191

**Non-obese impaired glucose tolerance**; Oral glucose (75 g) tolerance test; Non-esterified fatty acid; C-peptide/insulin ratio; Bezafibrate **25**, 199

**Oral glucose (75 g) tolerance test**; Non-esterified fatty acid; C-peptide/insulin ratio; Non-obese impaired glucose tolerance; Bezafibrate **25**, 199

**Pancreatic calculi**; Fibrocalculous pancreatic diabetes; Childhood onset; Tropical calcific pancreatitis; Chronic pancreatitis **25**, 137

**Polynesian**; Diabetic nephropathy; Glomerular filtration rate; Hyperfiltration **25**, 155

**Polyol pathway**; Aldose reductase inhibitor; Diabetic nephropathy; Glomerular morphometry; Mesangial expansion **25**, 141

**Prediction**; IDDM; Human; IVGTT; Reproducibility **25**, 131

**Pregnancy**; Diabetes; Impaired glucose tolerance; etal outcome **25**, 183

**Profound nerve fatigue**; Vibratory perception threshold; Repetitive nerve stimulation; Fasting hyperglycemia; Diabetes mellitus **25**, 27

**Quality of life**; Insulin regimens; Metabolic control; Insulin-dependent diabetes mellitus **25**, 111

**Rats**; 1,5-Anhydroglucitol; Aging; Diabetes mellitus; Humans **25**, 35

**Regeneration**; Galactosemia; Axo-glial dysjunction; ARI-treatment **25**, 117

**Repetitive nerve stimulation**; Vibratory perception threshold; Profound nerve fatigue; Fasting hyperglycemia; Diabetes mellitus **25**, 27

**Reproducibility**; IDDM; Human; Prediction; IVGTT **25**, 131

**Somatosensory evoked potentials**; Diabetic neuropathy; Non-insulin-dependent diabetes; Nerve conduction velocity **25**, 91

**Streptozotocin-injected rat**; Urinary albumin excretion; Heparin; Anionic site **25**, 83

**Total $B_{12}$ binding capacity**; Vitamin $B_{12}$; Glycemic control; Diabetes mellitus **25**, 13

**Tropical calcific pancreatitis**; Fibrocalculous pancreatic diabetes; Childhood onset; Pancreatic calculi; Chronic pancreatitis **25**, 137

**Tubular reabsorption**; Microtransferrinuria; Glomerular clearance; Non-insulin-dependent diabetes **25**, 169

**Type 1 (insulin-dependent) diabetes mellitus**; Lung functional tests; Diabetic microangiopathy; Albuminuria **25**, 161

**Type 1 diabetes mellitus**; Doppler echocardiography; Glomerular hyperfiltration **25**, 103

**Umbilical vein**; Intraportal insulin infusion; Insulin-like growth factor **25**, 1

**Urinary albumin excretion**; Streptozotocin-injected rat; Heparin; Anionic site **25**, 83

**Vibratory perception threshold**; Profound nerve fatigue; Repetitive nerve stimulation; Fasting hyperglycemia; Diabetes mellitus **25**, 27

**Vitamin $B_{12}$**; Glycemic control; Total $B_{12}$ binding capacity; Diabetes mellitus **25**, 13